普拉格雷
医学
替卡格雷
氯吡格雷
抗血栓
经皮冠状动脉介入治疗
急性冠脉综合征
P2Y12
阿司匹林
传统PCI
心脏病学
内科学
坎格雷洛
冠状动脉疾病
重症监护医学
心肌梗塞
作者
Pierre Sabouret,Luigi Spadafora,David L. Fischman,Waqas Ullah,Michel Zeitouni,Martha Gulati,Salvatore De Rosa,Michael P. Savage,Juan Pablo Costabel,Maciej Banach,Giuseppe Biondi‐Zoccai,Mattía Galli
标识
DOI:10.1016/j.ejim.2022.12.008
摘要
Dual antiplatelet therapy (DAPT) is the gold standard after acute coronary syndromes (ACS) or chronic coronary syndromes (CCS) undergoing percutaneous coronary intervention (PCI). Because local and systemic ischemic complications can occur particularly in the early phase (i.e. 1-3 months) after ACS or PCI, the synergistic platelet inhibition of aspirin and a P2Y12 inhibitor is of the utmost importance in this early phase. Moreover, the use of the more potent P2Y12 inhibitors prasugrel and ticagrelor have shown to further reduce the incidence of ischemic events compared to clopidogrel after an ACS. On the other hand, prolonged and potent antiplatelet therapy are inevitably associated with increased bleeding, which unlike thrombotic risk, tends to be stable over time and may outweigh the benefit of reducing ischemic events in these patients. The duration and composition of antiplatelet therapy remains a topic of debate in cardiology due to competing ischemic and bleeding risks, with guidelines and recommendations considerably evolving in the past years. An emerging strategy, called "de-escalation", consisting in the administration of a less intense antithrombotic therapy after a short course of standard DAPT, has shown to reduce bleeding without any trade-off in ischemic events. De-escalation may be achieved with different antithrombotic strategies and can be either unguided or guided by platelet function or genetic testing. The aim of this review is to summarize the evidence and provide practical recommendations on the use of different de-escalation strategies in patients with ACS and CCS.
科研通智能强力驱动
Strongly Powered by AbleSci AI